Chalmers School of Entrepreneurship

Chalmers School of Entrepreneurship offers a unique education where entrepreneurial students are given the opportunity to combine their creativity with tools, guidance and support that will allow them to shape a sustainable future. 

An action-based education where students are allowed to be in the frontier of innovation development, societal change and real value creation, and where reflection about societal challenges and about a sustainable leadership is encouraged

Chalmers School of Entrepreneurship is more than an education; it is a way for students to create real value from innovations and ideas, and a chance for them to act on the opportunities, needs and challenges of the world.

//News

Susanne Ollila gets ”Styrkeområdenas pris”

The Chalmers Areas of Advance’ award 2013 goes to Susanne Ollila, one of the researchers and lecturers associated with Chalmers School of Entrepreneurship. She gets the reward for her for her outstanding and pioneering work to create opportunities for collaboration across organizational boundaries.

The price of SEK 100,000, she plans to use in his research on open innovation arenas, an area where the jury believes that Susanne has worked her way to a key position at Chalmers.

Read the full article in swedish here. 

Alumni on top of Veckans Affärers list of 101 Super Talents

Jamal El-Mosleh (Alumni from GIBBS/BIO’06) is on top of Veckans Affärers list of 101 Super Talents (Årets Supertalang). Jamal is the CEO of Immunicum, which develops cancer vaccines.

- “It is an honor to be mentioned on this list, and to top it naturally feels very funny. Personally, I am grateful, but I hope above all that this publicity can help cancer patients”, says Jamal El-Mosleh, who is passionate about his mission to cure cancer.

At the age of 26, Jamal was recruited as the CEO of the new company Immunicum AB in Gothenburg. The company’s patented vaccine is based on over 30 years of research in the field of transplantation immunology and activates the body’s own immune system to attack tumour cells. The company has since its foundation five years ago moved from laboratory tests to currently conduct clinical phase I / II trials in renal cancer patients. To lead such a business requires hard work and knowledge, but also talent. The success of the company puts Jamal on top of Veckans Affärers list of Super Talents, which justifies the award of the following:

”Jamal El-Mosleh has single-handedly driven the company systematically from laboratory and animal studies to human clinical studies and preparation for vaccine production. He has taken the company through three rounds of private financing to an impending IPO, from a single patent to six patent families. He also has the communicative talent to understand complex research context and make them understandable to the general public. ”

Chalmers School of Entrepreneurship sends it´s warm and proud congratulations.

Immunicum AB (publ)

Immunicum developing vaccines for therapeutic treatment of cancer. The patented technology is based on over 30 years of research in the field of transplantation immunology and activates the body’s own immune system to attack harmful substances like tumour cells. Unlike most competing immunotherapies are vaccines possible to mass-produce.

Visit www.immunicum.se